Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641832 | 0.91 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11CES2 | |
| SCHEMBL1644033 | 0.90 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11CES2 | |
| SCHEMBL1642331 | 0.89 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1642475 | 0.89 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11CHRM4 | |
| SCHEMBL1643481 | 0.87 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL1643706 | 0.87 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11CDC7 | |
| SCHEMBL1643718 | 0.87 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11CDC7 | |
| SCHEMBL1643601 | 0.86 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1643725 | 0.86 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11CES2 | |
| SCHEMBL1643424 | 0.86 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098298-A1 | New Pyridin-3-Amine Derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-04-28 | — | — | US | claimed |
| US-20110098298-A1 | New Pyridin-3-Amine Derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-04-28 | — | — | US | disclosed |
| US-7906530-B2 | 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-03-15 | — | — | US | disclosed |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-09 | — | — | US | disclosed |
| EP-2049537-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2009-04-22 | — | — | EP | disclosed |
| EP-1987005-A2 | NEW PYRIDIN-3-AMINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008017461-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007096072-A2 | NEW PYRIDIN-3-AMINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098298-A1 | New Pyridin-3-Amine Derivatives | MAPK1, MAP4K2, MAPK3 | MAPK14 33/4885MAPK13 35/4885MAPK12 40/4885 |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | MAPK1, MAPK7, MAPKAPK2 | MAPK14 23/4885MAPK13 38/4885MAPK12 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.